Cargando…
FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976207/ https://www.ncbi.nlm.nih.gov/pubmed/36812740 http://dx.doi.org/10.1016/j.esmoop.2023.100883 |
| _version_ | 1784899019291492352 |
|---|---|
| author | Cervantes, A. Prager, G.W. |
| author_facet | Cervantes, A. Prager, G.W. |
| author_sort | Cervantes, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9976207 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99762072023-03-02 FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer Cervantes, A. Prager, G.W. ESMO Open Pro and Con Discussions Elsevier 2023-02-21 /pmc/articles/PMC9976207/ /pubmed/36812740 http://dx.doi.org/10.1016/j.esmoop.2023.100883 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Pro and Con Discussions Cervantes, A. Prager, G.W. FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title | FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title_full | FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title_fullStr | FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title_full_unstemmed | FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title_short | FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| title_sort | folfoxiri plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer |
| topic | Pro and Con Discussions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976207/ https://www.ncbi.nlm.nih.gov/pubmed/36812740 http://dx.doi.org/10.1016/j.esmoop.2023.100883 |
| work_keys_str_mv | AT cervantesa folfoxiriplusbevacizumabasstandardofcareforfirstlinetreatmentinpatientswithadvancedcoloncancer AT pragergw folfoxiriplusbevacizumabasstandardofcareforfirstlinetreatmentinpatientswithadvancedcoloncancer |